Wall Street brokerages expect that Incyte Co. (NASDAQ:INCY) will report earnings of $0.01 per share for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Incyte’s earnings, with the highest EPS estimate coming in at $0.25 and the lowest estimate coming in at ($0.09). Incyte reported earnings of $0.18 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 94.4%. The company is expected to report its next quarterly earnings results on Tuesday, August 8th.

According to Zacks, analysts expect that Incyte will report full-year earnings of ($0.76) per share for the current year, with EPS estimates ranging from ($0.88) to ($0.44). For the next financial year, analysts anticipate that the company will post earnings of $0.38 per share, with EPS estimates ranging from ($0.70) to $1.19. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Incyte.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. The business had revenue of $384.08 million for the quarter, compared to the consensus estimate of $359.19 million. Incyte had a return on equity of 50.38% and a net margin of 14.71%. The business’s revenue was up 45.8% on a year-over-year basis. During the same quarter last year, the business posted $0.12 EPS.

INCY has been the topic of a number of recent research reports. Goldman Sachs Group Inc lifted their price objective on Incyte from $116.00 to $149.00 and gave the company a “buy” rating in a report on Friday, January 27th. Nomura initiated coverage on Incyte in a report on Wednesday, March 1st. They set a “buy” rating on the stock. Royal Bank of Canada lifted their price objective on Incyte from $123.00 to $138.00 and gave the company an “outperform” rating in a report on Wednesday, February 15th. Cowen and Company reaffirmed an “outperform” rating on shares of Incyte in a report on Wednesday, March 8th. Finally, Zacks Investment Research downgraded Incyte from a “hold” rating to a “strong sell” rating in a report on Friday, February 17th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $139.93.

COPYRIGHT VIOLATION NOTICE: “Analysts Anticipate Incyte Co. (INCY) to Announce $0.01 Earnings Per Share” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/05/24/analysts-anticipate-incyte-co-incy-to-announce-0-01-earnings-per-share.html.

Shares of Incyte (NASDAQ:INCY) traded up 1.61% during mid-day trading on Wednesday, hitting $138.35. The company had a trading volume of 747,542 shares. Incyte has a 12-month low of $71.75 and a 12-month high of $153.15. The firm’s 50 day moving average is $126.92 and its 200-day moving average is $120.42. The firm’s market cap is $28.33 billion.

In related news, insider David W. Gryska sold 41,528 shares of the business’s stock in a transaction that occurred on Monday, April 10th. The shares were sold at an average price of $138.00, for a total value of $5,730,864.00. Following the completion of the transaction, the insider now owns 20,754 shares in the company, valued at approximately $2,864,052. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jean Jacques Bienaime acquired 1,000 shares of the company’s stock in a transaction that occurred on Friday, April 7th. The stock was bought at an average price of $139.48 per share, with a total value of $139,480.00. Following the transaction, the director now directly owns 2,177 shares in the company, valued at $303,647.96. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 3,000 shares of company stock valued at $398,770 and sold 137,968 shares valued at $19,395,245. Insiders own 13.70% of the company’s stock.

Several hedge funds have recently modified their holdings of INCY. Rock Springs Capital Management LP boosted its stake in shares of Incyte by 1.0% in the third quarter. Rock Springs Capital Management LP now owns 156,500 shares of the biopharmaceutical company’s stock valued at $14,756,000 after buying an additional 1,500 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of Incyte by 1.2% in the third quarter. HighTower Advisors LLC now owns 13,226 shares of the biopharmaceutical company’s stock valued at $1,244,000 after buying an additional 159 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Incyte by 74.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 36,745 shares of the biopharmaceutical company’s stock valued at $3,465,000 after buying an additional 15,687 shares during the last quarter. Jana Partners LLC acquired a new stake in shares of Incyte during the third quarter valued at approximately $5,505,000. Finally, BOKF NA acquired a new stake in shares of Incyte during the third quarter valued at approximately $385,000. Institutional investors own 92.62% of the company’s stock.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

12 Month Chart for NASDAQ:INCY

Get a free copy of the Zacks research report on Incyte (INCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Incyte Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Co. and related companies with MarketBeat.com's FREE daily email newsletter.